Table 1.
Patient Demographics and Clinical Status at Camrelizumab Initiation (n = 41) and Univariate Analysis of Prognostic Factors for Progression-Free Survival (PFS).
| Characteristic | Patients with UP after TACE (No, %; mean ± SD) | HR (95% CI) | P value |
|---|---|---|---|
| Gender | |||
| Male | 32 (78.0) | 1 | |
| Female | 9 (22.0) | 0.945 (0.404, 2.213) | .897 |
| Age (years) | 54.2 ± 11.4 | 1.011 (0.979, 1.044) | .503 |
| ECOG | |||
| 1 | 23 (56.1) | 1 | |
| 0 | 18 (43.9) | 0.886 (0.442, 1.775) | .732 |
| BCLC stage | |||
| C | 30 (73.2) | 1 | |
| B | 11 (26.8) | 0.682 (0.310, 1.501) | .342 |
| Largest diameter of tumor (cm) | 8.0 ± 4.9 | 1.009 (0.941, 1.082) | 799 |
| Hepatitis | |||
| Hepatitis B | 35 (85.4) | 1 | |
| Other | 6 (14.6) | 1.240 (0.474, 3.243) | .661 |
| α-fetoprotein level (ng/mL) | |||
| ＞400 | 20 (48.8) | 1 | |
| ≤400 | 21 (51.2) | 0.780 (0.390, 1.560) | .483 |
| Child–Pugh score | |||
| B | 5 (12.2) | 1 | |
| A | 36 (87.8) | 1.213 (0.367, 4.004) | .751 |
| Combination therapy | |||
| Yes | 23 (56.1) | 1 | |
| No | 18 (43.9) | 3.899 (1.818, 8.364) | .000 |
| TACE sessions before UP | 3.7 ± 3.4 | 1.036 (0.934, 1.150) | .500 |
| Tumor number | |||
| ≥3 | 36 (87.8) | 1 | |
| <3 | 5 (12.2) | 1.361 (0.469, 3.949) | .570 |
| Ascites | |||
| Present | 4 (9.8) | 1 | |
| Absent | 37 (90.2) | 1.620 (0.384, 6.827) | .511 |
| Extrahepatic spread | |||
| Present | 13 (31.7) | 1 | |
| Absent | 28 (68.3) | 1.247 (0.579, 2.689) | .573 |
| Vascular invasion | |||
| Present | 18 (43.9) | 1 | |
| Absent | 23 (56.1) | 0.933 (0.469, 1.856) | .844 |
| Interval time (weeks)a | |||
| >2 | 16 (39.0) | 1 | |
| <2 | 25 (61.0) | 0.570 (0.284, 1.146) | .115 |
| Baseline laboratory test result | |||
| TB (µmol/L) | 15.9 ± 8.4 | 1.031 (0.990, 1.072) | .138 |
| Albumin (g/L) | 35.1 ± 4.0 | 0.957 (0.883, 1.038) | .292 |
| PT (s) | 14.0 ± 1.0 | 1.025 (0.739, 1.421) | .883 |
| AST (µmol/L) | 53.1 ± 42.1 | 1.002 (0.997, 1.008) | .394 |
| ALT (µmol/L) | 38 ± 19.6 | 1.000 (0.983, 1.018) | .992 |
| Creatinine (µmol/L) | 63.8 ± 18.4 | 0.999 (0.979, 1.020) | .950 |
| PLR | 181.9 ± 117.6 | 1.003 (1.000, 1.005) | .032 |
| NLR | 4.0 ± 3.9 | 1.057 (0.975, 1.146) | .178 |
a
Interval time refers to the time interval between TACE and camrelizumab initiation.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PT, prothrombin time; SD, standard deviation; TACE, transcatheter arterial chemoembolization; TB, total bilirubin; UP, untreatable progression.